U.S. Markets closed
  • S&P 500

    4,397.94
    -84.79 (-1.89%)
     
  • Dow 30

    34,265.37
    -450.03 (-1.30%)
     
  • Nasdaq

    13,768.92
    -385.08 (-2.72%)
     
  • Russell 2000

    1,987.92
    -36.12 (-1.78%)
     
  • Crude Oil

    84.83
    -0.72 (-0.84%)
     
  • Gold

    1,836.10
    -6.50 (-0.35%)
     
  • Silver

    24.34
    -0.37 (-1.50%)
     
  • EUR/USD

    1.1348
    +0.0031 (+0.2724%)
     
  • 10-Yr Bond

    1.7470
    -0.0860 (-4.69%)
     
  • Vix

    28.85
    +3.26 (+12.74%)
     
  • GBP/USD

    1.3555
    -0.0045 (-0.3321%)
     
  • USD/JPY

    113.6500
    -0.4500 (-0.3944%)
     
  • BTC-USD

    35,362.55
    -1,209.85 (-3.31%)
     
  • CMC Crypto 200

    870.86
    +628.18 (+258.85%)
     
  • FTSE 100

    7,494.13
    -90.88 (-1.20%)
     
  • Nikkei 225

    27,522.26
    -250.64 (-0.90%)
     

MEDNAX's (MD) Earnings Beat Estimates in Q2, Improve Y/Y

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • MD

MEDNAX, Inc. MD reported second-quarter 2021 adjusted earnings of 41 cents per share, which beat the Zacks Consensus Estimate of 33 centsby 24.2%. Moreover, the bottom line improved 28.1% year over year.

The quarter witnessed strong patient volume trends in the quarter under review.

MEDNAX, Inc. Price, Consensus and EPS Surprise

MEDNAX, Inc. Price, Consensus and EPS Surprise
MEDNAX, Inc. Price, Consensus and EPS Surprise

MEDNAX, Inc. price-consensus-eps-surprise-chart | MEDNAX, Inc. Quote

Quarterly Details

The company generated revenues of $473 million, which beat the Zacks Consensus Estimate by 3.7% on the back of solid patient volumes. The top line fell 7.1% from the year-ago period’s level.

Same-unit revenues were up 13.4% year over year owing to net acquisition activity while same-unit revenues attributable to patient volume were up 9.5%.

General and administrative expenses increased 17.4% year over year to $71 million due to higher costs related to information-technology initiatives, reductions in salary expense, etc.

Total operating expenses rose 11% year over year to $422 million due to higher practice salaries and benefits, practise supplies and other operating expenses, and general and administrative expenses.

Interest expense of the company declined 40.3% on the back of its redemption of $750-million outstanding principle amount of 5.25% senior notes due 2023.

In the quarter under review, adjusted EBITDA totalled $65.5 million, up 17.6% year over year.

Business Update

The company completed the sale of a secondary corporate office building in the second quarter.

Financial Update (as of Jun 30, 2021)

The company had cash and cash equivalents of $338.1 million, which decreased 70% from the level as of Dec 31, 2020.

The company’s total debt, net of $998 million, was down 42.7% from the level at 2020 end while total assets worth $2.55 billion dropped 23.7% from the last-year end.

Cash flow used in operating activities was $70.4 million in the quarter under review compared with $97.5 million in second-quarter 2020.

The company left the second quarter with no outstanding borrowings under its $1.2-billion revolving credit facility.

Zacks Rank

MEDNAX currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Other Medical Sector Releases

Among other players from the medical space that have reported second-quarter earnings so far, the bottom-line results of UnitedHealth Group Incorporated UNH, Tenet Healthcare Corporation THC and HCA Healthcare, Inc. HCA beat estimates.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

UnitedHealth Group Incorporated (UNH) : Free Stock Analysis Report

Tenet Healthcare Corporation (THC) : Free Stock Analysis Report

MEDNAX, Inc. (MD) : Free Stock Analysis Report

HCA Healthcare, Inc. (HCA) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research